HFpEF Biomarker Study: Combined Diagnostic Value of NT-proBNP, DLK-1, PSP-D, and PCSK-9

58 HFpEF patient and 30 healthy control serum samples were analyzed via Olink proteomics to evaluate novel biomarkers. The combined detection of NT-proBNP, DLK-1, PSP-D, and PCSK-9 achieved an AUC of 0.794, outperforming individual markers. This prospective biomarker study by Liu Xiaobin was last updated in April 2026.

Use Cases

• Train machine learning models for HFpEF diagnosis based on the described biomarker panel.
• Compare diagnostic performance of individual versus combined biomarkers as detailed in the results.
• Investigate the role of PCSK-9, NT-proBNP, DLK-1, and PSP-D as risk factors for HFpEF.
• Validate proteomics-derived biomarker signatures for clinical application.

Strengths

• Includes specific performance metrics, such as an AUC of 0.794 for the four-biomarker combination.
• Data is derived from a controlled study with 58 HFpEF patients and 30 healthy controls.
• Results detail regression coefficients for identified risk factors (e.g., 1.061 for PCSK-9).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small at 103.5 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Serum samples analyzed using Olink proteomics technology; machine learning algorithms used for diagnostic performance comparison.

Time Range

Prospective study; specific collection period not stated.

Freshness

Last updated 2026-04-14 05:38:44; freshness should be verified.

Geography

Geographic coverage of patient and control groups is unknown.